Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group
Korean Journal of Pathology
;
: 100-106, 2013.
Artículo
en Inglés
| WPRIM
| ID: wpr-56554
ABSTRACT
Mutations of the epidermal growth factor receptor (EGFR) are the strongest predictive factor for response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. EGFR TKIs are approved in Korea as a first-line treatment for lung cancer patients with mutated EGFR. Rapid and accurate EGFR mutation testing is essential for patient selection and establishing targeted therapies with EGFR TKIs. Thus, a standard set of guideline recommendations for EGFR mutation testing suitable for the Korean medical community is necessary. In this article, we propose a set of guideline recommendations for EGFR mutation testing that was discussed and approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Quinazolinas
/
Proteínas Tirosina Quinasas
/
Selección de Paciente
/
Receptores ErbB
/
Clorhidrato de Erlotinib
/
Corea (Geográfico)
/
Pulmón
/
Neoplasias Pulmonares
Tipo de estudio:
Guía de Práctica Clínica
/
Estudio pronóstico
Límite:
Humanos
País/Región como asunto:
Asia
Idioma:
Inglés
Revista:
Korean Journal of Pathology
Año:
2013
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS